A multi-center, double-blind, placebo-controlled, randomized, parallel-group study to investigate the safety and efficacy of JNJ 31001074 in adults with attention-deficit/hyperactivity disorder
Latest Information Update: 26 Jun 2014
At a glance
- Drugs Bavisant (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Janssen Research & Development
- 04 May 2010 Actual patient number (32) added as reported by ClinicalTrials.gov.
- 04 May 2010 Actual patient number (32) added as reported by ClinicalTrials.gov.
- 01 Oct 2008 checked against clinicaltrials.gov record: added Association (Johnson and Johnson).